AdvertisementSupported byBy Chad BrayLONDON — GlaxoSmithKline said on Friday that it had agreed to acquire a pipeline of H.I.V. drugs in development from Bristol-Myers Squibb, in two deals that could be worth as much as $1.46 billion.Under the agreement, GlaxoSmithKline, the British drug maker, would pay $317 million for the late-stage H.I.V. drugs that the New York-based Bristol-Myers has been developing, and it would make an additional payment of up to $518 million depending on sales and development milestones.It would also pay $33 million for early-stage H.I.V. treatments being developed by Bristol-Myers, with additional payments of up to $587 million depending on future performance.“These acquisitions strengthen our leadership and innovation in H.I.V., one of our core areas of scientific research,” David Redfern, the GlaxoSmithKline chief strategy officer, said in a news release.The deals with Bristol-Myers are expected to bolster the drug pipeline of ViiV Healthcare, a specialist H.I.V. company owned by GlaxoSmithKline, the American drug maker Pfizer and Shionogi of Japan. ViiV Healthcare has 12 H.I.V. treatments on the market and posted sales of 1.5 billion pounds, or about $2.2 billion, in 2014.The two separate transactions are subject to regulatory approval and are expected to be completed in the first half of next year.Advertisement